Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma

Brian Keller; Anna M.E. Bruynzeel; Chad Tang; Anand Swaminath; Linda Kerkmeijer; William Chu

doi:10.3389/fonc.2021.634830

Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma

Brian Keller, Anna M.E. Bruynzeel, Chad Tang, Anand Swaminath, Linda Kerkmeijer, William Chu

Radiation Oncology

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Adaptive MR-guided radiotherapy (MRgRT) is a new treatment paradigm and its role as a non-invasive treatment option for renal cell carcinoma is evolving. The early clinical experience to date shows that real-time plan adaptation based on the daily MRI anatomy can lead to improved target coverage and normal tissue sparing. Continued technological innovations will further mitigate the challenges of organ motion and enable more advanced treatment adaptation, and potentially lead to enhanced oncologic outcomes and preservation of renal function. Future applications look promising to make a positive clinical impact and further the personalization of radiotherapy in the management of renal cell carcinoma.

Original language	English (US)
Article number	634830
Journal	Frontiers in Oncology
Volume	11
DOIs	https://doi.org/10.3389/fonc.2021.634830
State	Published - May 11 2021

Keywords

image-guided radiotherapy
MR-guided radiotherapy
MR-linac
renal cell carcinoma
stereotactic body radiotherapy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3389/fonc.2021.634830

Cite this

@article{2dc41d1c5a994012a423923314c1c907,

title = "Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma",

abstract = "Adaptive MR-guided radiotherapy (MRgRT) is a new treatment paradigm and its role as a non-invasive treatment option for renal cell carcinoma is evolving. The early clinical experience to date shows that real-time plan adaptation based on the daily MRI anatomy can lead to improved target coverage and normal tissue sparing. Continued technological innovations will further mitigate the challenges of organ motion and enable more advanced treatment adaptation, and potentially lead to enhanced oncologic outcomes and preservation of renal function. Future applications look promising to make a positive clinical impact and further the personalization of radiotherapy in the management of renal cell carcinoma.",

keywords = "image-guided radiotherapy, MR-guided radiotherapy, MR-linac, renal cell carcinoma, stereotactic body radiotherapy",

author = "Brian Keller and Bruynzeel, {Anna M.E.} and Chad Tang and Anand Swaminath and Linda Kerkmeijer and William Chu",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Keller, Bruynzeel, Tang, Swaminath, Kerkmeijer and Chu.",

year = "2021",

month = may,

day = "11",

doi = "10.3389/fonc.2021.634830",

language = "English (US)",

volume = "11",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy

T2 - The Next Step in the Treatment of Renal Cell Carcinoma

AU - Keller, Brian

AU - Bruynzeel, Anna M.E.

AU - Tang, Chad

AU - Swaminath, Anand

AU - Kerkmeijer, Linda

AU - Chu, William

PY - 2021/5/11

Y1 - 2021/5/11

N2 - Adaptive MR-guided radiotherapy (MRgRT) is a new treatment paradigm and its role as a non-invasive treatment option for renal cell carcinoma is evolving. The early clinical experience to date shows that real-time plan adaptation based on the daily MRI anatomy can lead to improved target coverage and normal tissue sparing. Continued technological innovations will further mitigate the challenges of organ motion and enable more advanced treatment adaptation, and potentially lead to enhanced oncologic outcomes and preservation of renal function. Future applications look promising to make a positive clinical impact and further the personalization of radiotherapy in the management of renal cell carcinoma.

AB - Adaptive MR-guided radiotherapy (MRgRT) is a new treatment paradigm and its role as a non-invasive treatment option for renal cell carcinoma is evolving. The early clinical experience to date shows that real-time plan adaptation based on the daily MRI anatomy can lead to improved target coverage and normal tissue sparing. Continued technological innovations will further mitigate the challenges of organ motion and enable more advanced treatment adaptation, and potentially lead to enhanced oncologic outcomes and preservation of renal function. Future applications look promising to make a positive clinical impact and further the personalization of radiotherapy in the management of renal cell carcinoma.

KW - image-guided radiotherapy

KW - MR-guided radiotherapy

KW - MR-linac

KW - renal cell carcinoma

KW - stereotactic body radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85107054811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107054811&partnerID=8YFLogxK

U2 - 10.3389/fonc.2021.634830

DO - 10.3389/fonc.2021.634830

M3 - Article

C2 - 34046341

AN - SCOPUS:85107054811

SN - 2234-943X

VL - 11

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 634830

ER -

Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this